Skip to main content
Whitehawk Therapeutics, Inc. logo

Whitehawk Therapeutics, Inc. — Investor Relations & Filings

Ticker · WHWK ISIN · US00032Q1040 LEI · 549300G3U7TKW1M58L09 US Professional, scientific and technical activities
Open in API
Filings indexed 516 across all filing types
Latest filing 2026-05-29 Regulatory Filings
Country US United States of America
Listing US WHWK

About Whitehawk Therapeutics, Inc.

https://ir.whitehawktx.com/

Whitehawk Therapeutics, Inc. is a preclinical-stage oncology company focused on developing advanced antibody-drug conjugate (ADC) therapies. The company applies next-wave platform technologies to established tumor biology to create treatments for difficult-to-treat cancers. Its portfolio features three ADC assets, which are engineered to overcome the limitations of first-generation predecessors through improved tumor targeting and clinical strategies. These assets are in-licensed from WuXi Biologics under an exclusive agreement for global development and commercialization.

Recent filings

Filing Released Lang Actions
S-3
Regulatory Filings Classification · 85% confidence The document is a Form S-3 registration statement (a SEC compliance prospectus under the Securities Act of 1933), used to register resale of shares by selling stockholders. It is neither a financial report (10-K, IR) nor a capital raise by the company (no proceeds to the company), nor any other specific category. Thus it falls into “Regulatory Filings” as a general SEC compliance filing that does not fit other categories.
2026-05-29 English
8-K
Regulatory Filings Classification · 93% confidence The document is a Form 8-K SEC Current Report detailing a corporate event under Item 8.01 “Other Events” and attaching a press release as Exhibit 99.1. It does not present financial statements nor serve as an annual or quarterly report, nor is it a proxy, earnings release, or prospectus. Therefore, it is a general regulatory filing and falls under the fallback category “Regulatory Filings” (RNS).
2026-05-21 English
8-K - Whitehawk Therapeutics, Inc. (0001422142) (Filer)
Capital/Financing Update Classification · 85% confidence The document is a Form 8-K current report announcing the entry into a Securities Purchase Agreement for PIPE financing, unregistered equity sales, and related registration rights—all components of a financing transaction. It is not an earnings release, board change, or regular financial report but specifically a capital raising event. Thus it falls under Capital/Financing Update.
2026-05-13 English
8-K - Whitehawk Therapeutics, Inc. (0001422142) (Filer)
Regulatory Filings
2026-05-07 English
3 Filing
Director's Dealing
2025-12-02 English
4 Filing
Director's Dealing
2025-12-02 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.